Progress and potential roles blood biomarkers of ischemic stroke in clinical setting

Kadek Adit Wiryadana , I Gede Putu Supadmanaba, Dewa Putu Gde Purwa Samatra

Kadek Adit Wiryadana
Undergraduate Student of Faculty of Medicine Udayana University, Denpasar Bali. Email:

I Gede Putu Supadmanaba
Biochemistry Department Faculty of Medicine Udayana University, Denpasar Bali

Dewa Putu Gde Purwa Samatra
Neurology Department Faculty of Medicine Udayana University, Denpasar Bali
Online First: July 02, 2017 | Cite this Article
Wiryadana, K., Supadmanaba, I., Samatra, D. 2017. Progress and potential roles blood biomarkers of ischemic stroke in clinical setting. Indonesia Journal of Biomedical Science 11(2): 19-29. DOI:10.15562/ijbs.v11i2.138

Stroke is one of the leading causes of death and disability which involving a complex pathophysiology with multiple mechanisms. Rapid treatment is necessary to terminate the disease progression, hence minimizing CNS damage and subsequent disability. Stroke diagnostic process composed of history taking, neurological examination and supplemented with neuroimaging. Imaging modalities such as CT-scan or MRI are essential in establishing a definitive diagnosis of ischemic stroke. However, the high cost and limited number made them inaccessible for those who have low or middle income which will delay the diagnosis and treatment. On the other hand, blood biomarker has potential in either diagnostic or prognostic aspect of ischaemic stroke management. It has a promising potential to aid diagnosis, determine the subtype of stroke, predicting the outcome or early neurological deterioration, and recurrence. It also could potentially help to assess the risk of hemorrhagic transformation, treatment selection, as well as to detect salvageable ischemic penumbra. Although it could not replace neuroimaging, blood-based biomarker assessment had lower cost and faster result. However, despite its promising potential, none of the blood biomarkers is currently used in clinical practice. Therefore, further studies are needed to develop biomarkers or panels of biomarkers with better sensitivity and specificity. This review provides a highlight and summary of blood biomarkers based on their potential application in a clinical setting.


Glushakova, O. Y., Glushakov, A. V, Miller, E. R., Valadka, A. B. & Hayes, R. L. Biomarkers for acute diagnosis and management of stroke in neurointensive care units. (2017). doi:10.4103/2394-8108.178546

Bharosay, A. et al. Correlation of brain biomarker neuron specific enolase (NSE) with degree of disability and neurological worsening in cerebrovascular stroke. Indian J. Clin. Biochem.27, 186–190 (2012).

Woodruff, T. M. et al. Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Mol Neurodegener6, 11 (2011).

Raman, K. et al. Peripheral Blood MCEMP1 Gene Expression as a Biomarker for Stroke Prognosis. Stroke47, 652–658 (2016).

Dichgans, M. et al. Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants. Stroke.45, 24–36 (2014).

Soler, E. P. & Ruiz, V. C. Epidemiology and risk factors of cerebral ischemia and ischemic heart diseases: similarities and differences. Curr. Cardiol. Rev.6, 138–49 (2010).

Mergenthaler, P. & Meisel, A. Do stroke models model stroke? Dis. Model. Mech.5, 718–25 (2012).

The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J. Clin. Epidemiol.41, 105–14 (1988).

Llombart, V. et al. Plasmatic retinol-binding protein 4 and glial fibrillary acidic protein as biomarkers to differentiate ischemic stroke and intracerebral hemorrhage. J. Neurochem.136, 416–424 (2016).

Guo, Y. W. et al. Pathophysiology and Biomarkers in Acute Ischemic Stroke - A Review. Trop. J. Pharm. Res.12, 1097–1105 (2013).

Jickling, G. C. & Sharp, F. R. Blood Biomarkers of Ischemic Stroke. Neurotherapeutics8, 349–360 (2011).

Castellanos, M. & Serena, J. Applicability of biomarkers in ischemic stroke. Cerebrovasc. Dis.24, 7–15 (2007).

Senn, R., Elkind, M. S. V, Montaner, J., Christ-Crain, M. & Katan, M. Potential role of blood biomarkers in the management of nontraumatic intracerebral hemorrhage. Cerebrovasc. Dis.38, 395–409 (2014).

Jiao, X. et al. The Role of Circulating Tight Junction Proteins in Evaluating Blood Brain Barrier Disruption following Intracranial Hemorrhage. Dis. Markers2015, (2015).

Deloulme, J. C. et al. Nuclear expression of S100B in oligodendrocyte progenitor cells correlates with differentiation toward the oligodendroglial lineage and modulates oligodendrocytes maturation. Mol. Cell. Neurosci.27, 453–465 (2004).

Lee, J. Y. et al. A role of serum-based neuronal and glial markers as potential predictors for distinguishing severity and related outcomes in traumatic brain injury. J. Korean Neurosurg. Soc.58, 93–100 (2015).

Yardan, T., Erenler, A. K., Baydin, A., Aydin, K. & Cokluk, C. Usefulness of S100B protein in neurological disorders. J. Pak. Med. Assoc.61, 276–281 (2011).

Wunderlich, M. T., Wallesch, C. W. & Goertler, M. Release of neurobiochemical markers of brain damage is related to the neurovascular status on admission and the site of arterial occlusion in acute ischemic stroke. J. Neurol. Sci.227, 49–53 (2004).

Montaner, J. et al. Differentiating ischemic from hemorrhagic stroke using plasma biomarkers: The S100B/RAGE pathway. J. Proteomics75, 4758–4765 (2012).

Knauer, C. et al. A biochemical marker panel in MRI-proven hyperacute ischemic stroke - a prospective study. BMC Neurol.12, 14 (2012).

Amarenco, P., Bogousslavsky, J., Caplan, L. R., Donnan, G. A. & Hennerici, M. G. Classification of stroke subtypes. Cerebrovasc. Dis.27, 493–501 (2009).

Adams, H. . et al. Classification of Subtype of Acute Ischemic Stroke. Definitions for use in multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke23, 35–41 (1993).

Ebinger, M. et al. Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: a randomized clinical trial. Jama311, 1622–1631 (2014).

Foerch, C. et al. Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke. Clin. Chem.58, 237–245 (2012).

Montaner, J. et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke39, 2280–2287 (2008).

Zi, W.-J. & Shuai, J. Plasma D-dimer levels are associated with stroke subtypes and infarction volume in patients with acute ischemic stroke. PLoS One9, e86465 (2014).

Singh, H. V. et al. Prognostic value of neuron specific enolase and IL-10 in ischemic stroke and its correlation with degree of neurological deficit. Clin. Chim. Acta419, 136–138 (2013).

Garcia-Berrocoso, T. et al. From brain to blood: New biomarkers for ischemic stroke prognosis. J. Proteomics94, 138–148 (2013).

Silacci, P. et al. Gelsolin superfamily proteins: Key regulators of cellular functions. Cell. Mol. Life Sci.61, 2614–2623 (2004).

Arimura, N., Menager, C., Fukata, Y. & Kaibuchi, K. Role of CRMP-2 in neuronal polarity. J Neurobiol58, 34–47 (2004).

Li, K. et al. Identification and expression of a new type II transmembrane protein in human mast cells. Genomics86, 68–75 (2005).

Thanvi, B., Treadwell, S. & Robinson, T. Early neurological deterioration in acute ischaemic stroke: predictors, mechanisms and management. Postgrad. Med. J.84, 412–7 (2008).

Kwan, J. & Hand, P. Early neurological deterioration in acute stroke: Clinical characteristics and impact on outcome. Qjm99, 625–633 (2006).

Cuadrado-Godia, E. Early neurological deterioration, easy methods to detect it. Indian J. Med. Res.141, 266–268 (2015).

Lin, L. C. et al. Predictors of early clinical deterioration after acute ischemic stroke. Am. J. Emerg. Med.29, 577–581 (2011).

Serena, J. et al. Neurological Deterioration in Acute Lacunar Infarctions: The Role of Excitatory and Inhibitory Neurotransmitters. Stroke32, 1154–1161 (2001).

Millán, M. et al. Biological signatures of brain damage associated with high serum ferritin levels in patients with acute ischemic stroke and thrombolytic treatment. Dis. Markers25, 181–8 (2008).

Bryan, N. S. & Grisham, M. B. Methods to detect nitric oxide and its metabolites in biological samples. Free Radic. Biol. Med.43, 645–57 (2007).

Llombart, V. et al. Fluorescent molecular peroxidation products a prognostic biomarker of early neurologic deterioration after thrombolysis. Stroke45, 432–437 (2014).

Dillard, C. & Tappel, A. Fluorescent damage products of lipid peroxidation. Methods Enzym.105, 337–341 (1984).

Jin, R., Yang, G. & Li, G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J. Leukoc. Biol.87, 779–789 (2010).

Castellanos, M. et al. Inflammation-Mediated Damage in Progressing. Steoke33, 982–987 (2002).

Bhatia, K., Mohanty, S., Tripathi, B. K., Gupta, B. & Mittal, M. K. Predictors of early neurological deterioration in patients with acute ischaemic stroke with special reference to blood urea nitrogen (BUN)/creatinine ratio & urine specific gravity. Indian J. Med. Res.141, 299–307 (2015).

Kelly, J. et al. Dehydration and venous thromboembolism after acute stroke. QJM - Mon. J. Assoc. Physicians97, 293–296 (2004).

Ribo, M. et al. Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb Haemost91, 1146–1151 (2004).

Staykov, D. & Gupta, R. Hemicraniectomy in malignant middle cerebral artery infarction. Stroke42, 513–516 (2011).

Serena, J. et al. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke36, 1921–1926 (2005).

Rubin, M. N. & Barrett, K. M. What to do With Wake-Up Stroke. 5, 161–172 (2015).

Rimmele, D. L. & Thomalla, G. Wake-up stroke : clinical characteristics , imaging findings , and treatment option – an update. 5, 1–7 (2014).

Meurer, W. J. & Barsan, W. G. Thrombolytic Therapy for Acute Ischemic Stroke. 40, 82–92 (2011).

Pan, R. et al. Blood Occludin Level as a Potential Biomarker for Early Blood Brain Barrier Damage Following Ischemic Stroke. Nat. Publ. Gr. 1–9 (2017). doi:10.1038/srep40331

Zhang, J., Yang, Y., Sun, H. & Xing, Y. Hemorrhagic transformation after cerebral infarction: current concepts and challenges. Ann. Transl. Med.2, 81 (2014).

Sussman, E. S. & Connolly, E. S. Hemorrhagic transformation: A review of the rate of hemorrhage in the major clinical trials of acute ischemic stroke. Front. Neurol.4 JUN, 1–7 (2013).

Barr, T. L. et al. Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke.41, e123-8 (2010).

Castellanos, M. et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke34, 40–45 (2003).

Montaner, J. et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation107, 598–603 (2003).

Castellanos, M. et al. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke35, 1671–1676 (2004).

Foerch, C. et al. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke38, 2491–2495 (2007).

Kazmierski, R., Michalak, S., Wencel-Warot, A. & Nowinski, W. L. Serum tight-junction proteins predict hemorrhagic transformation in ischemic stroke patients. Neurology79, 1677–1685 (2012).

Ribo, M. et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke35, 2123–2127 (2004).

Manuscript, A., Positive, G., Superantigen, B., Toxic, C. & Syndrome, S. NIH Public Access. 278, 4649–4667 (2012).

Segal, H. C. et al. Population-based study of blood biomarkers in prediction of subacute recurrent stroke. Stroke45, 2912–2917 (2014).

Giles, M. F. & Rothwell, P. M. Systematic review and pooled analysis of published and unpublished validations of the ABCD and ABCD2 transient ischemic attack risk scores. Stroke41, 667–673 (2010).

Giles, M. F. et al. Addition of Brain Infarction to the ABCD 2 Score (ABCD 2 I ) A Collaborative Analysis of Unpublished Data on 4574 Patients. 1907–1914 (2010). doi:10.1161/STROKEAHA.110.578971

Park, S.-Y. et al. Predictive value of circulating interleukin-6 and heart-type fatty acid binding protein for three months clinical outcome in acute cerebral infarction: multiple blood markers profiling study. Crit. Care17, R45 (2013).

Welsh, P. et al. Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc. Dis.27, 247–253 (2009).

Bruhn, T., Christensen, T. & Diemer, N. H. Uptake of glutamate is impaired in the cortical penumbra of the rat following middle cerebral artery occlusion: An in vivo microdialysis extraction study. J. Neurosci. Res.71, 551–558 (2003).

Frykholm, P. et al. Relationship between cerebral blood flow and oxygen metabolism, and extracellular glucose and lactate concentrations during middle cerebral artery occlusion and reperfusion: a microdialysis and positron emission tomography study in nonhuman primates. J. Neurosurg.102, 1076–1084 (2005).

Kiewert, C., Mdzinarishvili, A., Hartmann, J., Bickel, U. & Klein, J. Metabolic and transmitter changes in core and penumbra after middle cerebral artery occlusion in mice. Brain Res.1312, 101–107 (2010).

Bergeron, M., Yu, A. Y., Solway, K. E., Semenza, G. L. & Sharp, F. R. Induction of hypoxia-inducible factor-1 (HIF-1) and its target genes following focal ischaemia in rat brain. Eur. J. Neurosci.11, 4159–4170 (1999).

Sharp, F. R., Lu, a, Tang, Y. & Millhorn, D. E. Multiple molecular penumbras after focal cerebral ischemia. J. Cereb. Blood Flow Metab.20, 1011–1032 (2000).

No Supplementary Material available for this article.
Article Views      : 223
PDF Downloads : 163